



Increased expression of hypoxia-induced factor 1 α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Keiko Taniguchi-Ponciano, Eduardo Vadillo, Héctor Mayani, César Raúl Gonzalez-Bonilla, Javier Torres, Abraham Majluf, Guillermo Flores-Padilla, Niels Wachter-Rodarte, Juan Carlos Galan, Eduardo Ferat-Osorio, Francisco Blanco-Favela, Constantino Lopez-Macias, Aldo Ferreira-Hermosillo, Claudia Ramirez-Renteria, Eduardo Peña-Martínez, Gloria Silva-Román, Sandra Vela-Patiño, Carlos Mata-Lozano, Roberto Carvente-Garcia, Lourdes Basurto-Acevedo, Renata Saucedo, Patricia Piña-Sanchez, Antonieta Chavez-Gonzalez, Daniel Marrero-Rodríguez & Moisés Mercado

To cite this article: Keiko Taniguchi-Ponciano, Eduardo Vadillo, Héctor Mayani, César Raúl Gonzalez-Bonilla, Javier Torres, Abraham Majluf, Guillermo Flores-Padilla, Niels Wachter-Rodarte, Juan Carlos Galan, Eduardo Ferat-Osorio, Francisco Blanco-Favela, Constantino Lopez-Macias, Aldo Ferreira-Hermosillo, Claudia Ramirez-Renteria, Eduardo Peña-Martínez, Gloria Silva-Román, Sandra Vela-Patiño, Carlos Mata-Lozano, Roberto Carvente-Garcia, Lourdes Basurto-Acevedo, Renata Saucedo, Patricia Piña-Sanchez, Antonieta Chavez-Gonzalez, Daniel Marrero-Rodríguez & Moisés Mercado (2021) Increased expression of hypoxia-induced factor 1 α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients, *Annals of Medicine*, 53:1, 197-207, DOI: [10.1080/07853890.2020.1858234](https://doi.org/10.1080/07853890.2020.1858234)

To link to this article: <https://doi.org/10.1080/07853890.2020.1858234>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 21 Dec 2020.



Submit your article to this journal [↗](#)



Article views: 4075




View related articles [↗](#)



[View Crossmark data](#) 



Citing articles: 18 [View citing articles](#) 

ORIGINAL ARTICLE



Increased expression of hypoxia-induced factor 1 α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Keiko Taniguchi-Ponciano^{a*}, Eduardo Vadillo^{b*}, Héctor Mayani^b, César Raúl Gonzalez-Bonilla^c, Javier Torres^d, Abraham Majluf^e, Guillermo Flores-Padilla^f, Niels Wachter-Rodarte^g, Juan Carlos Galan^f, Eduardo Ferat-Osorio^h, Francisco Blanco-Favelaⁱ, Constantino Lopez-Macias^j, Aldo Ferreira-Hermosillo^a, Claudia Ramirez-Renteria^a, Eduardo Peña-Martínez^a, Gloria Silva-Román^a, Sandra Vela-Patiño^a, Carlos Mata-Lozano^{a,k}, Roberto Carvente-García^{a,k}, Lourdes Basurto-Acevedo^a, Renata Saucedo^a, Patricia Piña-Sánchez^b, Antonieta Chavez-Gonzalez^b, Daniel Marrero-Rodríguez^a and Moisés Mercado^a

^aUnidad de Investigación Médica en Enfermedades Endocrinas, UMAE Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^bUnidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^cTitular, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^dUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^eUnidad de Investigación Médica en trombosis, hemostasia y aterogénesis, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^fServicio de Medicina Interna, UMAE Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^gUnidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^hDivisión de Investigación en Salud, UMAE Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ⁱUnidad de Investigación Médica en Inmunología, UMAE Hospital de Pediatría, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^jUnidad de Investigación Médica en Inmunología, UMAE Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico city, Mexico; ^kAnalitek S.A. de C.V., CDMX, México

ABSTRACT

Background: COVID-19 counts 46 million people infected and killed more than 1.2 million. Hypoxaemia is one of the main clinical manifestations, especially in severe cases. HIF1 α is a master transcription factor involved in the cellular response to oxygen levels. The immunopathogenesis of this severe form of COVID-19 is poorly understood.

Methods: We performed scRNAseq from leukocytes from five critically ill COVID-19 patients and characterized the expression of hypoxia-inducible factor1 α and its transcriptionally regulated genes. Also performed metanalysis from the publicly available RNAseq data from COVID-19 bronchoalveolar cells.

Results: Critically-ill COVID-19 patients show a shift towards an immature myeloid profile in peripheral blood cells, including band neutrophils, immature monocytes, metamyelocytes, monocyte-macrophages, monocytoïd precursors, and promyelocytes-myelocytes, together with mature monocytes and segmented neutrophils. May be the result of a physiological response known as emergency myelopoiesis. These cellular subsets and bronchoalveolar cells express HIF1 α and their transcriptional targets related to inflammation (CXCL8, CXCR1, CXCR2, and CXCR4); virus sensing, (TLR2 and TLR4); and metabolism (SLC2A3, PFKFB3, PGK1, GAPDH and SOD2).

Conclusions: The up-regulation and participation of HIF1 α in events such as inflammation, immunometabolism, and TLR make it a potential molecular marker for COVID-19 severity and, interestingly, could represent a potential target for molecular therapy.

KEY MESSAGES

- Critically ill COVID-19 patients show emergency myelopoiesis.
- HIF1 α and its transcriptionally regulated genes are expressed in immature myeloid cells which could serve as molecular targets.
- HIF1 α and its transcriptionally regulated genes is also expressed in lung cells from critically ill COVID-19 patients which may partially explain the hypoxia related events.

ARTICLE HISTORY


Received 5 October 2020
Revised 7 November 2020
Accepted 25 November 2020

KEYWORDS

COVID-19; SARS-CoV-2; critically ill; scRNAseq; HIF1 α ; immature myeloid cells

CONTACT Daniel Marrero-Rodríguez ✉ dan.mar57@gmail.com CONACyT-Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, México D.F, 06720, México; Moisés Mercado ✉ moises.mercado@endocrinologia.org.mx Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, México D.F, 06720, México.

*These authors contributed equally to this work.

 Supplementary data for this article is available online at <https://doi.org/10.1080/07853890.2020.1858234>.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The coronavirus disease 2019 (COVID-19) epidemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly developed into a devastating pandemic [1]. As of today, the World Health Organization (WHO) has reported more than 46 million persons diagnosed with COVID-19 and over 1.2 million deaths worldwide [2]. It is associated with significant mortality in high risk patients, with poor prognostic features upon admission, such as advanced age, as well as a history of obesity, diabetes and hypertension. The spectrum of the disease is broad, and includes pneumonia, sepsis, and acute respiratory distress syndrome (ARDS) [3]. This complicated course occurs in the context of a cytokine storm characterized by overproduction of TNF, IL6, IL1 β , and G-CSF and generalized vascular hyperpermeability [3]. Viral particles spread through the respiratory mucosa infecting other cells, unleashing a series of immune responses, characterized by a reduction of T and B lymphocytes and an increment of monocytes and neutrophils [4–7]. The pathogenesis of this severe form of COVID-19 is poorly understood.

Hypoxaemia, defined as a decrease in the partial pressure of oxygen is an ominous sign of COVID-19, and it is usually an indicator of disease severity [8,9]. An oxygen saturation above 90% is associated with better outcomes [10]. Over 80% of COVID-19 patients in the intensive care unit have severe hypoxaemia [11]. A kind of “silent hypoxia” in which COVID-19 patients deteriorate rapidly without warning and develop respiratory failure has been described [12]. Hypoxia indicates an imbalance of oxygen delivery to tissues and leads to compromised function, which is quantitatively related to organ, tissue and even cell type. The hypoxia-inducible factors (HIF) are considered master regulators of oxygen homeostasis and are oxygen level sensitive [13,14]. HIF1 α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O₂ sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology [14]. Currently, there is scarce information regarding the expression of HIF in patients with severe COVID-19 and its potential involvement in the immunopathogenesis of this condition. Therefore, in the present work we carried out scRNAseq to identify the cell populations present in critically ill COVID-19 patients and to determine the expression of hypoxia-induced factor 1 α (HIF1 α) and its related genes.

Materials and methods

Patients and tissue samples

Blood samples from five critically ill patients with COVID-19 were collected in EDTA-coated tubes. Tissues were collected from patients diagnosed, treated and followed at the Internal Medicine Department of the Hospital de Especialidades, Centro Médico Nacional Siglo XXI of the Instituto Mexicano del Seguro Social in April 2020. A family member of each participating patient signed an informed consent and the study protocol was approved by the Comisión Nacional de Ética e Investigación Científica del Instituto Mexicano del Seguro Social in accordance to the Helsinki declaration. SARS-CoV-2 infection was corroborated by RT-qPCR at an official federal government reference laboratory.

Sample preparation, scRNAseq library generation and sequencing

Peripheral blood from the five critical COVID-19 patients was collected in EDTA-coated tubes, and immune cells were isolated according to standard centrifugation methods followed by red blood cell lysis.

Chromium Next GEM Single Cell 3' Reagent Kits v3.1 and the protocol from 10X Genomics was followed as recommended by the manufacturers. Briefly, immune cells were pooled in a single tube and were suspended in 1x phosphate buffered saline (PBS) to 700–1200 cells per μ l. Cell suspension was loaded in Chromium Next GEM Chip G and sorted in the Chromium Controller from 10X Genomics. The Cell-Gel Beads in Emulsion (GEMs) were then incubated to generate the barcoded cDNA. cDNA was cleaned using Dynabeads and washed, followed by cDNA amplification and SPRI selection. The retrieved cDNA was enzymatically fragmented, end-repaired, poly-A tailed and ligated. Size selection, adaptor ligation and amplification were done. Sequencing was done using NextSeq 550 System High-Output Kit (300 cycles) in NextSeq 500 system (Illumina) according to 10X Genomics specifications: Read 1 = 28 cycles, Read 2 = 91 cycles, Index 1 = 8 cycles. All quality control steps were carried out using 4200 TapeStation System (Agilent) with High Sensitivity D1000 Screen Tape, whereas the concentration was calculated using Qubit 2.0 Fluorometer with Kit High Sensitivity assays.

scRNAseq bioinformatic analysis

Partek Flow software was used with scRNAseq toolbox. First the tags were trimmed and then the reads were

aligned using STAR 2.7.3a algorithm to human genome hg38. UMI's were deduplicated and barcode filtered. Following criteria were then applied to each cell, i.e. gene number between 200 and 6000, UMI count above 300 and mitochondrial gene percentage below 20%. To quantify the transcriptome human hg38 Ensembl transcripts release 99 was used. Counts per million, add 1.0 Log 2.0 were the normalization parameters. Healthy donors' datasets were downloaded from 10X Genomics website and analyzed using Loupe Browser from 10X Genomics. Data has been deposited in Sequence Read Archive hosted by National Centre for Biotechnology Information under accession number PRJNA635580.

Markers used to circumscribe cell populations

Clusters were categorized by analyzing differentially expressed genes according to previously published data obtained from human samples [15–19].

Dimensionality reduction and clustering

The filtered and normalized gene-barcode matrix was analyzed by principal components, then graph based and uniform manifold approximation and projection (UMAP) for dimension reduction using default parameters was carried out.

Cellular alterations analysis

ENRICH (https://maayanlab.cloud/Enrichr/) was used to understand the biological meaning behind the resulting list of genes, to analyze the gene ontology and pathway information of significantly deregulated genes in the different cellular subsets.

In silico analysis of RNAseq files of cells derived from bronchoalveolar lavage fluid

Paired end fastq files were downloaded from BIGD-GSA and SRI from NCBI. Accession numbers are CRA002390 and SRR10571724, SRR10571730, and SRR10571732. Data files consisted in 3 COVID-19 patients bronchoalveolar lavage fluid (BALF) and 3 bronchoalveolar fluid lavage controls. Fastq files quality control was performed using FastQC v. 0.11.9. Samples adapter were trimmed with the Cutadapt v tool. 2.10.

BALF samples duplicates were spotted using Picard v. 2.22.4, the RNAseq reads alignments were done using STAR tools v. 2.7.3a, with the parameters

previously described [20]. The RNAseq reading count was carried out using the Rsubread package with the annotations of Homo sapiens GRCh38.99 downloaded from Ensembl. Subsequent analyzes were performed using the stable Gene ID identifier with BioMart annotations: Ensembl Genes 100, Human genes (GRCh38.p13), the identifier was translated to HGNC symbol to facilitate biological interpretation. The BALF counts were subjected to quality control using the NOISeq package, biases associated with length, GC content, RNA composition and batch effect, were identified and removed. BALF samples were processed using full-quantile normalization for GC content and length, finally, the ARSYN function was used to eliminate batch effect. The normalization process was carried out using the NOISeq and EDASeq packages in R. Differentially expressed genes were calculated on the normalized counts using the noiseqbio function of the NOISeq package, using the predefined parameters and filtered by a probability greater than 0.99.

Results

Clinical features of critically ill COVID-19 patients

Five male patients with a mean age of 47.8 ± 6.6 years (range 41–57) were studied. Interestingly, four of five patients presented hypoxaemia upon hospital admission to the hospital with O₂ saturation levels ranging from 40–84% of. The initial SOFA score of the five patients ranged between 2 and 4. All patients had radiological evidence of alveolar occupation and ground glass appearance on imaging studies and required intubation and invasive mechanical ventilation 3 to 7 days after admission as well as hemodynamic collapse that required vasopressor support. All five patients were treated with enoxaparin, hydroxychloroquine, azithromycin or clarithromycin as well as lopinavir and ritonavir; three received high dose glucocorticoids (hydrocortisone or dexamethasone). Three of the five patients died of ARDS and multiorgan failure (Table 1).

Immature myeloid cell populations in critically ill COVID-19 patients

We have previously reported that, as compared to healthy adults, lymphoid cell subsets, such as B and T lymphocytes as well as NK cells, are present in low quantities in critically ill COVID-19 patients, whereas cells of myeloid origin predominate. Interestingly, immature myeloid cell populations, such as band neutrophils, metamyelocytes, promyelocytes-myelocytes,

Table 1. Characteristics of critically ill patients with COVID-19.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age, yrs	57	46	43	41	52
Gender	M	M	M	M	M
% Oxygen saturation at admission	40	50	NA	57	84
SOFA score at admission	4	2	2	2	2
BMI, kg/cm ²	29	26.3	31	24	29
Comorbidities	OW	None	DM, OW	None	DM, OW
Time from admission to intubation, days	4	3	5	3	5
Leukocytes per mm ³	9130	8760	7760	8900	5060
Lymphocytes, x 10 ³ /mm ³	650	520	160	1130	1600
Hb, g/dL	16.4	15.9	17	12.9	15.8
Platelets, x 10 ³ /mm ³	193	357	380	523	169
CRP, mg/L	23.6	35	11.9	27	11.6
Procalcitonin, ng/mL	2.32	1.87	0.07	0.22	0.33
D-Dimer, ng/mL	2410	3320	1100	2980	2020
Fibrinogen, mg/dL	834	788	753	789	773
Final outcome	Dead	Dead	Dead	Alive	Alive

OW: overweight; DM: type 2 diabetes mellitus; BMI: body mass index; SOFA: sequential organ failure assessment; NA: not available; M: male.

monocytoid precursor, and immature monocytes prevailed. Mature lineages such as segmented neutrophils, mature monocytes and monocyte-macrophages were also observed (Figure 1) [20].

Altered cellular pathways in immune cells from critically ill COVID-19 patients

Myeloid cell population subsets presented alterations in: (1) neutrophil-mediated immunity, (2) cellular response to type I interferon and (3) cell cycle control, DNA and RNA processing. The lymphoid cellular subset alterations were mostly related to ribosome biogenesis as well as RNA processing and modification. Along with the gene ontology analysis the algorithm compares the gene list input data with publicly available information and thus, our gene set lists were in accordance with COVID-19 data (Supplementary Figure 1).

HIF1 α expression in leukocytes from critically ill COVID-19 patients

Once the blood cell populations were identified, we looked for HIF1 α gene expression. As shown in Figure 2(A), HIF1 α gene was expressed in all myeloid lineages to a greater extent than in lymphoid cells. This was particularly evident in the mature monocyte population. Since HIF1 α is a transcription factor that acts as a *trans* regulator, we searched for HIF1 α -regulated genes potentially involved in COVID-19 immunity. Among these immune related genes, we found an increased expression of CXCL8 or Interleukin-8, a chemokine involved in the migration of mature neutrophils to the site of infection in most myeloid cell subsets, and almost no expression in lymphoid populations and

monocytoid precursors (Figure 2(B)). In keeping with the increased expression of CXCL8, the genes for chemokine receptors CXCR2 (Figure 2(C)), CXCR4 (Figure 2(D)), as well as CXCR1, were also expressed at increased levels in most myeloid lineages. It is noteworthy that lymphoid cells did express the CXCR4 gene, but showed no expression of the CXCR2 gene, which can explain the exacerbated inflammatory response characteristic of these patients [21]. Interestingly, we found expression of Toll like receptor-2 and -4 (TLR2 and TLR4) in most myeloid populations, which could be related to SARS-CoV-2 sensing (Figure 2(E,F)).

Along with the identified genes regulated by HIF1 α , we found expression of genes related to metabolism such as solute carrier family 2 member 3 (SLC2A3) also known as GLUT3, 6-phosphofructo-2-kinase (PFKFB3), phosphoglycerate kinase 1 (PGK1) and glyceraldehyde-3-P-dehydrogenase (GAPDH) (Figure 3). GAPDH is related to neutrophil survival through the inhibition of programmed cell death [22].

We also found expression of superoxide dismutase 2 (SOD2), involved in the metabolism of reactive oxygen species; vimentin (VIM), a type III intermediate filament and plasminogen activator urokinase receptor (PLAUR), which is related to plasminogen activation.

Considering that HIF1 α function is controlled by different factors, we also evaluated the expression of the Von Hippel Lindau (VHL) and prolyl-4-hydroxylase (P4HA1) genes, two of the main inhibitors of HIF1 α function. Indeed, these two molecules are involved in the ubiquitination and degradation of HIF1 α . In keeping with the increased expression of HIF1 α and target genes observed, we found that neither VHL nor P4HA1 were expressed by the peripheral blood cells of critically ill COVID-19 patients (Figure 2(G,H)).




Figure 1. Uniform manifold approximation and projection (UMAP) showing the identification of 12 cell clusters in critically ill COVID-19 patients. Immature myeloid populations, such as band neutrophils, metamyelocytes, promyelocytes-myelocytes, monocytoid precursor, and immature monocytes, as well as mature lineages, such as segmented neutrophils, mature monocytes and monocyte-macrophages are observed.

We next evaluated the potential interaction between HIF1 α and their transcriptional targets by assessing the simultaneous presence of their mRNAs in the same single cells (Figure 4). As shown in Figure 4(A), a significant proportion of myeloid cells co-expressed HIF1 α and CXCL8. We also observed a predominance of cells co-expressing HIF1 α and TLR2 (Figure 4(B)) as well as HIF1 α and SOD2 (Figure 4(C)). It is noteworthy that among the different myeloid subsets, mature monocytes were the ones that exhibited co-expression of most of the analyzed genes.

Finally, we evaluated the expression of HIF1 α and its transcriptional targets in peripheral blood cells from healthy donors. To do so, we analyzed 10X Genomics publicly available datasets. We observed that HIF1 α expression was lower as compared to the expression observed in COVID-19 patients (Figure 5).

Similar results were observed for genes such as CXCL8, CXCR2, PLAUR, TLR4 and SOD2 (Figure 5).

HIF1 α expression and its transcriptionally regulated genes in SARS-CoV-2 infected lungs

Lung is one of the main organs affected by SARS-CoV-2 infection. We have previously described the alteration of hyaluronan, glycosaminoglycan and mucopolysaccharides metabolism which could, in part, explain the presence of a viscous fluid found in the interstitial space that reduces lung compliance and thus, effective ventilation [23]. Lung cells from COVID-19 patients show expression of HIF1 α , TLR2, TLR4, PFKFB3, CXCR1, -2 and -4, SOD2, PLAUR (Figure 6) and other genes expressed in immature myeloid cells.




Figure 2. Expression levels of HIF1 α and transcriptionally regulated target genes in peripheral blood cell lineages. HIF1 α (A), CXCL8 (B), CXCR2 (C), CXCR4 (D), TLR2 (E), TLR4 (F) VHL (G) and P4HA1 (H) mRNA's expression.




Figure 3. Violin plots from HIF1 α transcriptionally regulated genes. (A–C) The expression of SOD2, SLC2A3 and VIM, respectively, in peripheral blood cells from critically ill COVID-19 patients.

Discussion

Using a scRNAseq approach we have found a distinctive predominance of immature cell lineages of myeloid origin and a reduced number of lymphoid lineages in patients with life-threatening respiratory distress syndrome due to SARS-CoV-2 infection, which

is in accordance with recently reported data [6–8]. Collectively, our results are in accordance with similar observations were severe COVID-19 patients presented marked changes in immune cell composition and phenotype, reflecting an emergency granulopoiesis [24]. It is noteworthy that a similar blood profile has



Figure 4. Simultaneous expression of HIF1 α and target genes on the same single cell. (A) The expression of HIF1 α (green), CXCL8 (blue) and CXCR4 (red). (B) The expression of HIF1 α (green), TLR2 (red) and TLR4 (blue), and panel C the expression of HIF1 α (green), SOD2 (blue) and PLAUR (red).




Figure 5. Cell populations and HIF1 α gene expression identified in peripheral blood cells from healthy individuals. (A) The cell subsets identified in healthy donors. (B–D) The expression of HIF1 α , PLAUR and TLR4 mRNA, respectively.

been observed in patients with acute parvovirus B19, cytomegalovirus and Epstein-Barr viral infection [20]. In line with this, it has been reported in severe COVID-19 patients, as well as, some bacterial infections that a high neutrophil-to-lymphocyte ratio is associated to multi-organ damage and mortality [25].

Hypoxia and inflammation are unequivocally linked [26] and are two of the main physiological consequences of SARS-CoV-2 infection, particularly in

severe cases. In this study we present scRNAseq data regarding HIF1 α -related gene expression in peripheral blood leukocytes from critically ill COVID-19 and characterized the different cell subpopulations. HIF1 α is a heterodimeric transcription factor sensitive to oxygen and induced under hypoxic conditions [27]. The HIF1 α *trans* element can regulate the expression of CXCL8 [28], CXCR1, CXCR2 [29] and CXCR4 [30]. CXCL8 expression can be stimulated by interleukin




Figure 6. Circos plot from the BALF cells transcriptome from COVID-19 patients. Inner ring is the scatter plot representing each transcript identified followed by chromosome number and size, the outer ring present HIF1 α -related gene expression.

(IL) 6, TNF α , hypoxia [31] and viral infection [32] in cells such as monocytes, neutrophils, epithelial cells and fibroblasts [33]. CXCL8 is a chemokine that exerts its pro-inflammatory functions throughout the CXCR1 and CXCR2 receptors. CXCL8 and its receptors contribute to pathogen elimination, through the transient activation of ERK, AKT, SRC and FAK leading to activation of neutrophils [32]. The expression of CXCL8, which is present in COVID-19 patients, is considered a potential prognostic factor in acute respiratory distress syndrome (ARDS) [34] and lung injury [35].

The SARS-CoV-2 viral entry depends upon binding of viral spike (S) protein to the host cell surface protein angiotensin-converting enzyme 2 (ACE2) [36].

Under physiological conditions, there is an equilibrium between ACE1 and ACE2. However, under hypoxic conditions the ACE2 gene is negatively regulated by HIF1 α . It has been suggested that increased levels of ACE2 positively correlate with COVID-19, thus the stabilization of HIF1 α which in turn, down regulates the ACE2 gene, could improve the outcomes in COVID-19 patients [37,38].

The immunopathological outcomes are most likely induced by the host-virus interaction. The interaction between viral antigen and host immune cells results in an exacerbated inflammatory response [39]. In the present study, we also found high expression of both TLR2 and TLR4 genes in peripheral blood leukocytes of

severe COVID-19 cases. The viral Spike protein can be recognized by TLR2 [40] and TLR4 [39]. Upregulation of TLR2 and TLR4 has been found in the context of infections with the original SARS-CoV [41]. TLR4 constitutes one of the most efficient innate immune receptors, triggering pro-inflammatory responses after binding to the pathogenic ligand, and this interaction could be useful for developing drugs [39].

Metabolic reprogramming of innate immune cells occurs during hyperinflammatory states. Immune cells contribute to systemic changes in metabolism by altering their metabolic profiles in response to the immunological state. Therefore, therapeutic modulation of immune cell metabolism could alter the inflammatory state and thus improve patient prognosis [42]. Inflammation and hypoxia are inherently linked, and hypoxia is a well-known glycolysis driver as oxygen deficit results in limited OXPHOS [43]. Previous studies have shown that the molecular mechanisms underlying the switch from OXPHOS to glycolysis during innate immune cell response require HIF1 α [42]. Among the HIF1 α responsive genes, we found expression of those related to carbohydrate metabolism, such as SLC2A3/GLUT3, PFKFB3, PGK1 and GAPDH [44]. HIF signalling pathway activation in neutrophils results in an increased survival of these cells, β 2 integrin expression, production of antimicrobial peptides and glycolysis. Neutrophils use high rates of Warburg-like glycolysis for ATP generation. The absence of HIF1 α leads to reduced ATP pools resulting in a profound impairment of the inflammatory response [45]. HIF1 α can also regulate nitric oxide production, pentose phosphate pathway, OXPHOS and arginase metabolism [42]. Overall, immunometabolism is now considered an indispensable regulator of immunity, with HIF1 α playing a central role, modulating the function of various immune cell subsets [45]. The expression of HIF1 α has been previously found to be a sepsis marker [42].

HIF1 α participates in the regulation of a plethora of cellular events such as metabolism of ROS through the regulation of SOD2 [46], the regulation of cytoskeleton through VIM type III filament, which also participates in inflammation [47], and PLAUR which activates plasminogen and activates a cascade of extracellular proteases [48]. Interestingly, the expression of this gene could be used as a predictor of severe respiratory failure [49] which is consistent with our results.

Conclusion

In conclusion, in the present study, we have demonstrated the expression of HIF1 α and its

transcriptionally regulated genes, in myeloid cells, including both mature and immature subsets, present in peripheral blood of critically ill COVID-19 patients. The up-regulation and participation of HIF1 α in relevant events such as inflammation, immunometabolism, and TLR supports its use as molecular marker for COVID-19 severity and as a potential candidate for targeted therapy.

Acknowledgments

The authors would like to thank to Xiaowen Wang from Partek Inc. for the exceptional technical support provided.

Disclosure statement

At the time that this project was carried out RCG and CML worked for Analitek S.A. de C.V. which supplied research reagents, but also they were members of Dr. Mercado lab. Analitek S.A. de C.V. did not influence the results nor design of the protocol. The rest of the authors declare not competing interests.

Ethical approval

All participating patients were recruited with signed informed consent and ethical approval from the Comisión Nacional de Ética e Investigación Científica del Instituto Mexicano del Seguro Social in accordance with the Helsinki declaration.

Funding

This work was partially supported by grants 289499 from Fondos Sectoriales Consejo Nacional de Ciencia y Tecnología Mexico and R-2015-785-015 from Instituto Mexicano del Seguro Social (MM). DMR is a recipient of the National Council for Science and Technology Fellowship “Catedra CONACyT” program.

Data availability statement

Data have been deposited in Sequence Read Archive hosted by National Centre for Biotechnology Information under accession number PRJNA635580.

Author contributions

MM, DMR and KTP conceived, designed and coordinated the project, performed scRNAseq experiments, analysed, discussed data and prepared the manuscript. EV, HM, CRGB, JT, AM, NWR, FBF, AFH, CRR, EPM, GSR, SVP, CML, RCG, LBA, RS, PPS and ACG performed scRNAseq experiments, analysed, discussed and interpreted biological data, wrote the paper. CLM, JCG, EFO, GFP, provided the biological sample, retrieved the immune cells and collect clinical data.

References

- [1] Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis.* 2020;
- [2] World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020.
- [3] Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med.* 2020;8(6):e46–e7.
- [4] Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis.* 2020;221(11):1762–1769.
- [5] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* (10223)2020; 395:507–513.
- [6] Guo C, Li B, Ma H, et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. *Nat Commun.* 2020;11(1):3924.
- [7] Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov.* 2020;10.1038/s41421-020-0168-9
- [8] Zini G, Bellesi S, Ramundo F, et al. Morphological anomalies of circulating blood cells in COVID-19. *Am J Hematol.* 2020;95(7):870–872.
- [9] Sarkar M, Niranjana N, Banyal PK. Mechanisms of hypoxemia. *Lung India.* 2017;34(1):47–60.
- [10] Kashani KB. Hypoxia in COVID-19: sign of severity or cause for poor outcomes. *Mayo Clin Proc.* 2020;95(6): 1094–1096.
- [11] Xie J, Covassin N, Fan Z, et al. Association between hypoxemia and mortality in patients with COVID-19. *Mayo Clin Proc.* 2020;95(6):1138–1147.
- [12] Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. *Clin Pract.* 2020;10(2):1271.
- [13] Choudhury R. Hypoxia and hyperbaric oxygen therapy: a review. *Int J Gen Med.* 2018;11:431–442.
- [14] Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. *Mol Cell.* 2010;40(2):294–309.
- [15] Hoogendijk AJ, Pourfarzad F, Aarts CEM, et al. Dynamic transcriptome-proteome correlation networks reveal human myeloid differentiation and neutrophil-specific programming. *Cell Rep.* 2019;29(8): 2505–2519 e4.
- [16] Grassi L, Pourfarzad F, Ullrich S, et al. Dynamics of transcription regulation in human bone marrow myeloid differentiation to mature blood neutrophils. *Cell Rep.* 2018;24(10):2784–2794.
- [17] Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell.* 2011;144(2): 296–309.
- [18] Lambert C, Preijers F, Yanikkaya Demirel G, et al. Monocytes and macrophages in flow: an ESCCA initiative on advanced analyses of monocyte lineage using flow cytometry. *Cytometry B Clin Cytom.* 2017;92(3): 180–188.
- [19] Tang-Huau TL, Gueguen P, Goudot C, et al. Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway. *Nat Commun.* 2018;9(1):2570.
- [20] Vadillo E, Taniguchi-Ponciano K, Lopez-Macias C, et al. A shift towards an immature myeloid profile in peripheral blood of critically ill COVID-19 patients. *Arch Med Res.* 2020;S0188-4409(20)31785-9.
- [21] Sadiku P, Walmsley SR. Hypoxia and the regulation of myeloid cell metabolic imprinting: consequences for the inflammatory response. *EMBO Rep.* 2019;20(5): e47388.
- [22] Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1 α -dependent NF- κ B activity. *J Exp Med.* 2005; 201(1):105–115.
- [23] Andonegui-Elguera S, Taniguchi-Ponciano K, Gonzales-Bonilla CR, et al. Molecular alterations prompted by SARS-CoV-2 infection: induction of hyaluronan, glycosaminoglycan and mucopolysaccharide metabolism. *Arch Med Res.* 2020;51(7):645–653.
- [24] Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat Med.* 2020; 26(7):1070–1076.
- [25] Mousavi SA, Rad S, Rostami T, et al. Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. *Hematology.* 2020; 25(1):383–388.
- [26] Vanderhaeghen T, Vandewalle J, Libert C. Hypoxia-inducible factors in metabolic reprogramming during sepsis. 2020;287(8):1478–1495.
- [27] Masoud GN, Li W. HIF-1 α pathway: role, regulation and intervention for cancer therapy. *Acta Pharm Sin B.* 2015;5(5):378–389.
- [28] Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. *Curr Top Microbiol Immunol.* 2010;345:105–120.
- [29] Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF- κ B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. *Oncogene.* 2007;26(52): 7333–7345.
- [30] Ishikawa T, Nakashiro K, Klosek SK, et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. *Oncol Rep.* 2009;21(3): 707–712.
- [31] Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. *Theranostics.* 2017;7(6):1543–1588.
- [32] Tang FS, Van Ly D, Spann K, et al. Differential neutrophil activation in viral infections: Enhanced TLR-7/8-mediated CXCL8 release in asthma. *Respirology.* 2016; 21(1):172–179.
- [33] Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. *Int J Inflam.* 2011;2011:908468.
- [34] Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement

- of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev.* 2020;53:25–32.
- [35] Russo RC, Garcia CC, Teixeira MM, et al. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. *Expert Rev Clin Immunol.* 2014;10(5):593–619.
- [36] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181(2):271–280 e8.
- [37] Afsar B, Kanbay M, Afsar RE. Hypoxia inducible factor-1 protects against COVID-19: a hypothesis. *Med Hypotheses.* 2020;143:109857.
- [38] Zhang R, Wu Y, Zhao M, et al. Role of HIF-1 α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol.* 2009;297(4):L631–L640.
- [39] Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. *J Med Virol.* 2020;92(10):2105–2113.
- [40] Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. *Virus Res.* 2009;142(1-2):19–27.
- [41] Hu W, Yen YT, Singh S, et al. SARS-CoV regulates immune function-related gene expression in human monocytic cells. *Viral Immunol.* 2012;25(4):277–288.
- [42] Fitzpatrick SF. Immunometabolism and sepsis: a role for HIF? *Front Mol Biosci.* 2019;6:85.
- [43] Corcoran SE, O'Neill LA. HIF1 α and metabolic reprogramming in inflammation. *J Clin Invest.* 2016;126(10):3699–3707.
- [44] Liu W, Shen SM, Zhao XY, et al. Targeted genes and interacting proteins of hypoxia inducible factor-1. *Int J Biochem Mol Biol.* 2012;3(2):165–178.
- [45] Krzywinska E, Stockmann C. Hypoxia, metabolism and immune cell function. *Biomedicines.* 2018;6(2):56.
- [46] Gao YH, Li CX, Shen SM, et al. Hypoxia-inducible factor 1 α mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma. *Biochem Biophys Res Commun.* 2013;435(1):46–51.
- [47] Su L, Pan P, Yan P, et al. Role of vimentin in modulating immune cell apoptosis and inflammatory responses in sepsis. *Sci Rep.* 2019;9(1):5747.
- [48] Gilder AS, Natali L, Van Dyk DM, et al. The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres. *Sci Rep.* 2018;8(1):2982.
- [49] Rovina N, Akinosoglou K, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. *Crit Care.* 2020;24(1):187.